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Abstract
Objectives The objectives of this study were to investigate
the population pharmacokinetics of posaconazole in
immunocompromised children, evaluate the influence of
patient characteristics on posaconazole exposure and per-
form simulations to recommend optimal starting doses.
Methods Posaconazole plasma concentrations from pae-
diatric patients undergoing therapeutic drug monitoring
were extracted from a tertiary paediatric hospital database.
These were merged with covariates collected from elec-
tronic sources and case-note reviews. An allometrically
scaled population-pharmacokinetic model was developed
to investigate the effect of tablet and suspension relative
bioavailability, nonlinear bioavailability of suspension,
followed by a step-wise covariate model building exercise
to identify other important sources of variability.
Results A total of 338 posaconazole plasma concentrations
samples were taken from 117 children aged 5 months to
18 years. A one-compartment model was used, with tablet
apparent clearance standardised to a 70-kg individual of
15 L/h. Suspension was found to have decreasing
bioavailability with increasing dose; the estimated sus-
pension dose to yield half the tablet bioavailability was
99 mg/m2. Diarrhoea and proton pump inhibitors were also
associated with reduced suspension bioavailability.
Conclusions In the largest population-pharmacokinetic
study to date in children, we have found similar covariate
effects to those seen in adults, but low bioavailability of
suspension in patients with diarrhoea or those taking con-
current proton pump inhibitors, which may in particular
limit the use of posaconazole in these patients.
Key Points
Posaconazole is unlicensed for children under 13
years of age and its pharmacokinetics have not
widely been reported in this population group; our
study provides a large cohort in this age group
receiving both tablets and an oral suspension
A population-pharmacokinetic model has revealed
saturable suspension bioavailability, and reduced
bioavailability in patients taking proton pump
inhibitors and those with diarrhoea
Based on simulations from our model, dosing and
therapeutic drug monitoring guidelines are provided
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1 Introduction
Invasive fungal disease (IFD) remains an important cause
of morbidity and mortality in immunocompromised chil-
dren [1, 2]. Despite the development of new diagnostic
methods and the availability of new antifungal agents, the
incidence and mortality from IFD remains unacceptably
high. Posaconazole is a second-generation, broad-spec-
trum, fluorinate triazole that inhibits ergosterol synthesis in
the fungal cell wall. It is active against most pathogenic
yeasts and moulds, including Aspergillus spp., Candida
spp., Cryptococcus spp., filamentous fungi, dimorphic
fungi and endemic mycoses [3–6].
Despite currently being unlicensed for use in the pae-
diatric population, posaconazole has successfully been
used for the prevention and treatment of IFD in this group
[7], and is recommended for prophylaxis against invasive
Aspergillus and Candida infections after allogeneic
haematopoietic stem cell transplantation in adolescents [7].
Additionally, posaconazole has been used as a salvage
treatment for IFD with favourable outcomes [8, 9].
Two oral formulations of posaconazole are currently
available, a gastro-resistant tablet and an oral suspension.
Posaconazole pharmacokinetics are variable, particularly
during absorption and with the suspension formulation, and
very limited paediatric data have been published to date
[10]. Pharmacokinetic models to inform optimal dosing in
infants and young children, in particular, are therefore
lacking.
Therapeutic drug monitoring (TDM) for most triazoles
is recommended owing to high inter-individual variability
and the potential for drug–drug interactions. According to
the British Society for Medical Mycology, a posaconazole
target trough concentration of greater than 0.7 and 1 mg/L
should be used for the prophylaxis and treatment of IFD,
respectively, and as yet no upper limit for toxicity has been
defined [11].
Our study aimed to develop a population-pharmacoki-
netic model of posaconazole in a large cohort of paediatric
patients. Focussing on children aged 12 years and under,
the resulting model was then used to identify patient groups
at risk of sub-optimal posaconazole exposure, and to sug-
gest initial dosing.
2 Patients and Methods
2.1 Patients and Data Collection
In- and out-patients at a tertiary paediatric hospital
receiving posaconazole between January 2010 and
December 2016 were studied. Patients receiving
posaconazole for prophylaxis or the treatment of IFD and
who had at least one TDM sample taken, and had full
dosing and sample timing history available were included.
The time and date of the posaconazole TDM sample, along
with the reported concentration, were extracted from
electronic TDM records. For inpatients, dosing history was
taken from electronic nursing administration history,
whereas for outpatients the time of the last dose was taken
from the TDM request. In addition, demographics, con-
comitant medications, presence of diarrhoea on the day of
sampling and purpose (prophylaxis or treatment) were
collected from electronic records. Medical notes including
clinic letters and inpatient treatment records coinciding
with each sampling occasion were read to extract infor-
mation on the indication and the presence of diarrhoea.
Because the data were collected by clinical staff retro-
spectively and were anonymised prior to analysis, ethical
review and the need for informed consent were waived by
the institute’s research and development office.
For dosing data from the electronic prescribing and
administration system, all doses from the first dose to the
first TDM sample were included. Thereafter, only the doses
in the preceding 48 h prior to a TDM sample were used,
with the first of these assumed to be at steady state. For
outpatient samples, the preceding dose was assumed to be
at steady state based on the reported dose and frequency.
During the recruitment period, posaconazole assays
were sent to the following accredited laboratories for
analysis: Department of Microbiology, Wythenshawe
Hospital, Manchester, UK; the Mycology Reference Lab-
oratory, Leeds, UK; and Mycology Reference Laboratory,
Bristol, UK. The lower limits of quantification ranged
between 0.07 and 0.2 mg/L.
2.2 Population-Pharmacokinetic Modelling
Because most samples were pre-dose troughs and
posaconazole is known to have a long elimination half-life,
a one-compartment model with first-order absorption was
used. Allometric scaling with exponents of 0.75, 1 and -
0.25 on clearance (CL), central volume and absorption rate
constant (Ka) were added a priori, and a sigmoidal matu-
ration function based on postmenstrual age was tested [12].
Because posaconazole tablets have been reported to
have higher bioavailability than the suspension [13], and
tablet pharmacokinetics are linear in the therapeutic range
[14], whereas suspension has been shown to have nonlinear
absorption [15], the following expression was used to
describe relative bioavailability between a tablet and a
suspension, and the nonlinear suspension bioavailability:
F ¼ Ftab  D
Dþ bdose
;
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where F is the bioavailability of the suspension relative to
the tablet, Ftab is the apparent tablet bioavailability that was
fixed to 1, D is the dose in mg/m2, and bdose is the estimated
dose in mg/m2 to yield a 50% decrease in bioavailability of
the suspension relative to tablets.
A step-wise covariate model (SCM) building exercise
with a forward inclusion limit set to a p value of 0.05 and
backwards elimination limit set to a p value of 0.01 was
then undertaken to identify whether any of the following
dichotomous covariates were associated with suspension
apparent bioavailability: diarrhoea, treatment/prophylaxis,
macrolides, echinocandins, terbinafine, ciclosporin, tacro-
limus, mycophenolate, rifamycins, carbamazepine, pheny-
toin, histamine H2-receptor antagonists, proton pump
inhibitors (PPIs) or valaciclovir. The following concomi-
tant medications were also tested on CL: macrolides,
echinocandins, ciclosporin, tacrolimus, mycophenolate,
rifampicin, carbamazepine, phenytoin or valaciclovir.
Model diagnostics included plots of observations vs.
population predictions and conditional weighted residuals
vs. time and prediction. Simulation properties were tested
with a visual predictive check. Parameter stability was
investigated using a non-parametric bootstrap. Modelling
was undertaken using NONMEM Version 7.3 (ICON PLC,
Dublin, Ireland) [16] with the first-order conditional esti-
mation algorithm with interaction. A combined additive
plus proportional error model was used throughout model
building, and then removal of the additive or proportional
element considered at the final model step.
A decrease in - 2 log likelihood [the objective function
value (OFV) in NONMEM] between two nested models
asymptotically follows a v2 distribution with degrees of
freedom equal to the number of additional parameters. This
was used to guide covariate inclusion with a p value
threshold set to 0.01. Perl-speaks NONMEM (University of
Uppsala, Sweden) was used for the SCM (forward inclu-
sion p \ 0.05, backward elimination p \ 0.01), visual
predictive check and bootstrap preparation [17], and data
manipulations and plotting were performed using R Ver-
sion 3.2 (R Foundation, Vienna, Austria) [18].
A dataset of 1000 hypothetical patients for each sig-
nificant covariate in the final model and for each formu-
lation was created by re-sampling from the demographics
(weight, age) of the original dataset. Using this dataset and
the final model, simulations of steady-state trough con-
centration were produced to assess probability of target
attainment for prophylaxis (0.7 mg/L) and treatment
(1 mg/L) targets [11].
3 Results
3.1 Data Characteristics
The initial dataset contained 580 posaconazole plasma
concentrations from 128 individuals. Owing to incomplete
data entry in outpatient TDM records that could not be
reconciled from clinic letters, 242 samples were excluded,
leaving a total of 338 posaconazole plasma concentrations
from 117 children. There were 22 samples below the limit
of quantification, which were substituted with a value of
lower limit of quantification/2. Most samples were taken
following administration of a posaconazole suspension
(326). The median age was 5.7 years, which included 22
infants aged less than 2 years, 47 young children aged
2–6 years and 36 children aged 7–12 years. Demographic
details are given in Table 1, and an illustration of doses
administered by age is given in Fig. 1.
3.2 Population Pharmacokinetics
The base structural model with allometric scaling centred
on 70 kg and inter-individual variability on CL only gave
parameter estimates of 86.5 L/h, 1439.6 L and 0.09/h for
apparent clearance (CL/F), apparent volume and Ka,
respectively. The addition of a sigmoidal maturation
function gave no improvement in fit, whereas adding a
categorical covariate of a change in relative bioavailability
with suspension compared with a tablet yielded a decrease
in OFV of 10.11 (p = 0.0015). Allowing suspension
bioavailability relative to a tablet to change with dose
(bdose in the expression above) yielded a decrease in OFV
of 23 (p\ 0.001) compared with the model of suspension
having a fixed decrease in bioavailability regardless of
dose.
During model building, flip-flop kinetics became
apparent (Ka being estimated to be larger than elimination
rate constant). Thereafter, Ka was fixed to literature values
of 0.588/h for tablets [19], and 0.197/h for suspensions
[15]. The difference in OFV between this model and the
estimated Ka and V models was 7.63, indicating a very
similar fit.
In the SCM, following the backward elimination step,
diarrhoea and concurrent PPI administration both resulted
in significant improvements in fit when applied to a
decrease in suspension bioavailability (DOFV 11.06 and
35.53 corresponding to p = 0.001 and p\ 0.001, respec-
tively). Parameter estimates and bootstrap results are given
in Table 2. Figure 2 shows goodness-of fit plots for the
final model.
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3.3 Simulations of Steady-State Trough
Concentration
Simulations showed that patients aged 7–12 years taking
300 mg in a tablet form once a day (the adult treatment
dose) would have a 24% probability of achieving a trough
concentration of[1 mg/L and a 33% of achieving trough
concentrations of[0.7 mg/L for prophylaxis. Giving the
same total daily dose split three times per day would
achieve a probability of target attainment (PTA) of 44 and
59% for treatment and prophylaxis, respectively, whereas
200 mg three times per day would achieve a PTA of 72 and
80% for treatment and prophylaxis, respectively.
Suspension bioavailability affected the PTA markedly,
in particular in patients with diarrhoea and those taking
PPIs. For example, a child aged between 6 months and
2 years taking 200 mg four times per day would have a
PTA of 68 and 80% for treatment and prophylaxis,
respectively, but this falls to 29 and 44% for patients with
diarrhoea and those taking PPIs. In this case, doubling the
dose to 400 mg four times per day only improves the PTA
to 33 and 48%. Plots of simulated target attainment vs.
dose are given in Fig. 3.
4 Discussion
To the best of our knowledge, this is the first population-
pharmacokinetic analysis of posaconazole tablets and sus-
pension in immunocompromised children. We studied the
pharmacokinetics in 117 patients, including 105 aged under
13 years. This is a larger cohort than the largest published
adult clinical cohort to date by Dolton et al. [20], who
studied 102 patients. Our major finding is that as soon as
children are able to swallow whole tablets, they should be
given the tablet formulation because a poor and saturable
suspension bioavailability, particularly in patients with
diarrhoea or those taking concurrent PPI therapy, means a
Table 1 Demographics of all patients, and those included in the pharmacokinetic analysis after removing data with missing dose history or
sample timing information
Variable All patients (n = 128) PK patients (n = 117)
No. of TDM samples 580 338
No. of samples/patients, median (range) 5 (1–14) 3 (1–11)
Speciality, BMT/Haem/Imm/othera 94/7/19/8 87/6/17/7
Age, years (range) 5.9 (0.5–18.9) 5.7 (0.5–18.5)
Weight, kg (range) 17.92 (6.05–71) 17.8 (6.05–74.8)
Sex, male/female 47/81 43/74
Dose, mg (range) 200 (32–700) 200 (32–630)
Dose, mg/kg (range) 12.99 (2.58–48.95) 13.11 (2.67–48.95)
Dose, mg/m2, (range) 326 (84–921) 326 (84–921)
Concentration, mg/L (range) 0.96 (0.07–4.99) 0.8 (0.07–4.99)
Sample time after dose, h(range) 6.96 (0.02–24.78) 6.52 (0.02–24.78)
Dose frequency, doses/day (range) 3 (1–4) 3 (1–4)
% samples when patient had diarrhoea 18 20
% samples when patient also taking PPI 61 68
% samples when patient also taking H2 receptor antagonist 28 32
BMT bone marrow transplant, Haem haematology, Imm immumology, H2 histamine H2-receptor antagonist, PK pharmacokinetic, PPI proton
pump inhibitor, TDM therapeutic drug monitoring
a‘Other’ includes patients undergoing solid organ transplantation, those from gastroenterology, and surgical patients
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Fig. 1 Absolute dose (in milligrams) administered vs. age (in years).
The left-hand plot shows initial dosing prior to therapeutic drug
monitoring (TDM) sampling and the right-hand plot shows doses
administered after at least one TDM sample. Grey circles represent
suspension doses and black filled points represent tablets
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therapeutic target attainment with suspension may be as
low as 30% even on the highest feasible dose (Fig. 3).
A one-compartment model with inter-individual vari-
ability best described the pharmacokinetics of
posaconazole in this study (Fig. 2). This was consistent
with previous adult models [15, 19, 20]. Our estimated CL/
F and apparent volume related to the tablet formulation and
standardised to a 70-kg individual were 14.95 L/h and
Table 2 Parameter estimates from the final model (the NONMEM model code is given in the Electronic Supplementary Material)
Parameter Estimate (%RSE) IIV %CV (%RSE) Bootstrap median (95% CI) Bootstrap IIV %CV (95% CI)
CL/F, L/h 14.95 (34.5) 63 (23.9) 14.6 (6.3–34.1) 63 (49–79)
V/F, L 201.7 (38.8) – 213 (80.7–904.3) –
Ka suspension/h 0.197 (fixed) – – –
Ka tablet/h 0.588 (fixed) – – –
bdose, mg/m
2 99 (44.4) – 97.6 (36.5–341.7 ) –
hD -0.33 (28) – -0.32 (-0.52 to -0.13) –
hP -0.42 (14.9) – -0.42 (-0.53 to -0.27) –
Proportional error, %CV 47.29 (0.2) – 46.43 (36.92–53.48) –
Additive error, mg/L 0.02 (82.7) – 0.01 (0.001–0.07) –
bdose estimated dose in mg/m
2 for suspension bioavailability to drop to half that of the tablet, CI confidence interval, CL/F apparent clearance, CV
coefficient of variation, Ka absorption rate constant, hD fractional decrease in suspension bioavailability with patients with diarrhea, hP fractional
decrease in suspension bioavailability with patients taking proton pump inhibitors, RSE relative standard error, V/F apparent volume
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Fig. 2 Goodness-of-fit plots for
the final model. Top row:
population (pop.) predictions vs.
observations, individual (ind.)
predictions vs. observations.
Bottom row: conditional
weighted residuals (CWRES)
vs. pop. prediction (PRED), and
PRED-corrected visual
predictive check showing
model-simulated 95%
confidence intervals for the
simulated 2.5, 50 and 97.5th
percentiles (shaded areas)
compared with observed
percentiles (lines)
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201.68 L, respectively. In a recent study of adults, CL/F
and apparent volume were estimated to be 7.3 L/h and 420
L, respectively [19], which fall within the 95% confidence
intervals of our estimates (Table 2). Fixing the absorption
rate to that previously reported in adults had a negligible
effect on model fit, and the flat profiles, the fact our data
did not include any patients sampled after their first dose,
and the limited number of samples in the absorption phase
all account for this. The residual variability was rather high
in our study (Table 2), reflecting the fact that these were
observational TDM data on a drug with highly variable
pharmacokinetics. However, model diagnostics show a
reasonable fit (Fig. 2). We did not find a significant rela-
tionship between age and posaconazole CL/F, which could
be owing to the fact that our youngest patient was 6 months
old, whereas rapid pharmacokinetic maturation tends to
occur in the neonatal to early infant age group [12].
The gastro-resistant tablet formulation has been widely
reported to have improved bioavailability over the sus-
pension [21–24]. In addition, suspension bioavailability has
previously been reported to be saturable in adults [25–28],
although we are not aware of this relationship having
previously been modelled using the population approach.
In children, we found a dose–proportional relationship with
our estimated dose to reach a 50% relative bioavailability
reduction in tablets relative to the suspension of 99 mg/m2.
In this expression, we scaled dose by body surface area
under the assumption that gastrointestinal surface area and
body surface area would be correlated, and that gastroin-
testinal surface area is important for absorption. Validating
this assumption is not straight-forward because accurate
measurement of gastrointestinal surface area is difficult
[29], and no extensive studies appear to have been con-
ducted on how it might scale with age [30]. However, our
model did provide an adequate fit to our data and our
estimate ought to be robust because we studied a large dose
range (Table 1).
Gastrointestinal complications are common in cancer
patients and haematopoietic stem cell transplantation
recipients. In this analysis, 20% of patients had diarrhoea
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Fig. 3 Simulated probability of trough concentration being[1 mg/L
(top row) for treatment or[0.7 mg/L (bottom row) for 8- and 6-h
dosing split by age group. The solid line represents tablets, the dashed
line represents the suspension, the dotted line represents patients
taking the suspension also receiving proton pump inhibitors, the
dot/dashed line represents patients receiving the suspension who also
had diarrhoea, and the long dashed line represents patients receiving
the suspension and proton pump inhibitors and who had diarrhoea.
The grey horizontal line represents a 50% probability of target
attainment
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during treatment, and the majority were receiving con-
comitant acid suppression therapy (Table 1). Diarrhoea
results in increased gastric emptying with reduced gas-
trointestinal residence time. This disruption in gastroin-
testinal function was associated with a significant reduction
in bioavailability and therefore target attainment (Fig. 3).
The association of diarrhoea with decreased posaconazole
exposure has previously been noted in adults [20, 31], with
Dolton et al. [20] finding a 45% reduction in apparent
bioavailability. Our estimate of 33% shows a similar
relationship in children.
Concomitant use of PPIs was associated with a 42%
reduction in relative bioavailability. Concomitant PPI
therapy has been shown to be associated with decreased
bioavailability in adults [32–35], and our estimate is sim-
ilar to that obtained by Dolton et al. [20], who found a 45%
decrease. In contrast with PPIs, fewer studies have shown
the potential effect of histamine H2-receptor antagonists on
posaconazole exposure [20, 31], and we also did not find
this effect, suggesting the more potent acid suppression of
PPIs [36, 37] limits posaconazole absorption. It is unlikely
that this interaction is cytochrome P450 mediated because
posaconazole undergoes limited metabolism primarily by
UDP-glucuronosyltransferase UGT1A4 [38]. Information
on whether the dose was taken with food and whether
mucositis was present was unavailable in our study but
these may also have been significant covariates based on
adult experience [20]. Partly because of the low number of
children in our data taking tablets, and also the fact that
PPIs and histamine H2-receptor antagonists have been
shown not to affect posaconazole tablet bioavailability in
adults [39], we did not perform covariate analysis on the
tablet formulation.
Patients undergoing haematopoietic stem cell trans-
plantation usually require immunosuppressive agents for
the prevention and treatment of graft vs. host disease in
combination with antifungal prophylaxis for IFD. Con-
current use of posaconazole potentially results in increased
drug exposure of several immunosuppressive drugs
including ciclosporin, tacrolimus, sirolimus and everolimus
[40–42]. We did not find these agents to affect posacona-
zole pharmacokinetics, but future work on our data to
investigate and quantify the effect of posaconazole on
immunosuppressant levels is planned. We did not find
phase II glucuronide enzyme inducers such as rifampicin or
phenytoin to be significantly associated with either
posaconazole CL/F or bioavailability during the SCM. The
likely explanation for this is that our study contained a
small proportion of samples taken concurrently with these
drugs (5 and 1%, respectively), but it is also possible that
immaturity of drug-metabolising enzyme expression in
younger children means such interactions are less pro-
nounced. We also tested prophylaxis vs. treatment as a
covariate with the concern that the differences seen may be
owing to data inaccuracies because prophylaxis patients
were more likely to be outpatients with less reliable dosing
history than inpatients for whom we had electronic
administration data. The fact that this did not emerge as a
covariate on CL/F or bioavailability indicates no such bias
was present.
In Fig. 1, we show the dosing by age split between
initial dose and post-TDM dosing. The key features of this
plot are that a flat 200-mg dose was often used, regardless
of age, and the following TDM doses were generally
increased, particularly in younger patients. Clinical prac-
tice has evolved in our centre from weight-scaled dosing to
fixed 200-mg dosing regardless of age, based on repeated
failures to achieve therapeutic target trough concentrations.
The added insight provided by simulations from our model
(Fig. 3) indicates that absolute dose increases above
200 mg are rather futile owing to the saturable bioavail-
ability. For example, a 1-year-old individual with a body
surface area of 0.5 m2 receiving 100, 200 or 400 mg of
suspension will have a relative bioavailability of 0.33, 0.2
or 0.11, respectively. Increasing from 100 to 200 mg
decreases the bioavailability by 40%, whereas increasing
from 200 to 400 mg decreases the bioavailability by almost
half, explaining the marginal increases in trough concen-
tration with increasing doses. In common with findings for
itraconazole [43], increasing the frequency is more suc-
cessful, but dose administrations of greater than four times
per day are simply impractical.
Whilst we have modelled the largest paediatric
posaconazole pharmacokinetics dataset to date, our study
does have limitations that should be considered when
interpreting the results. First, as mentioned above, these
were retrospective TDM data collected over 7 years in a
single centre, and owing to inconsistent reporting of the
sample time and dose time in the outpatient data, we had to
exclude 242 samples. Furthermore, we are likely to have
collected more data on patients with poor target attainment
because those patients would be sampled more frequently
following dose escalation. Ideally, we would have run a
prospective study with optimally designed pharmacokinetic
sampling [44], but this would have resulted in a smaller
dataset and then potentially missing covariates of interest.
Having said this, maximum likelihood methods should not
be biased by this type of data and our prediction-corrected
visual predictive check showed good agreement with
observations. Further data pooling experience from multi-
ple centres would however be useful to confirm our find-
ings. We have also performed simulations aiming for
trough concentration targets based on adult data [11],
whereas either a different target or use of a metric such as
the area under the curve may be more appropriate in
children. Whilst we did not collect outcome data during
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this particular study, there is a clear need for such data in
this population.
5 Conclusion
Our study illustrates the challenge of achieving therapeutic
posaconazole trough concentrations, particularly in infants
and young children administered a posaconazole suspen-
sion. In a child with diarrhoea and concomitant PPI use,
therapeutic targets are unlikely to be reached in a large
proportion of patients, with a low probability of target
attainment with any feasible dose (Table 3).
Therefore, there is an urgent need first for the intra-
venous formulation to be studied for IFD treatment in this
population, and second, for therapeutic targets to be studied
in this population to ascertain whether treatment and pro-
phylactic benefits maybe retained with trough concentra-
tions below 1 or 0.7 mg/L.
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